Breast cancer is the second leading cause of death among cancers in women. 1 in 8 women are diagnosed with breast cancer in their lifetime. In 2018 it was expected that 232,000 new BC cases would arise and about a 17% death chance. There are different types of breast cancers that are based on the expression of receptors. Breast cancer patients normally show expression of estrogen receptor (ER), progesterone receptor (PR) and amplified human epidermal growth factor (HER2). Cases that lack expression of these receptors are referred to as Triple negative breast cancer (TNBC). and a third type is one that shows HER2 amplification. A protein kinase that our research focuses on is the S6K1 protein which is a downstream kinase target of the mTOR pathway. S6K1 is an important regulator of cancer cell migration, invasion, and ultimately metastasis. Our research laboratory focuses on synthesizing derivatives of 1,3-dioxoisoindolinylamide as S6K1 specific inhibitors. The reaction scheme is a 5-step process to synthesize 4,6-diaminoisoindoline-1,3-dione (RJ1) and to further react them with acyl/alkyl/aryl halides for functionalization at the 6 position.

Synthesis of derivatives of 4,6-diaminoisoindoline-1,3-dione as S6K1 inhibitors

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.